A Phase 2/3 interventional study of AMX0035 and Placebo in Progressive Supranuclear Palsy, PSP and Neurodegenerative Diseases, sponsored by Amylyx Pharmaceuticals Inc.. Completed at 62 sites in 5 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Amylyx Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 18th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 2/3, and was the 71st registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
Adam Boxer · Sites in United States
Ages 41–86
Novartis Pharmaceuticals · Sites in United States, Australia, Belgium and 9 more countries
Ages 41–81
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 18 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 43 across 102 interventional studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 43 across the 52 interventional studies, 200 across the 31 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 84 have an industry lead sponsor. The 10 most frequent:
Amylyx Pharmaceuticals Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Amylyx Pharmaceuticals Inc. has 1 study filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
8 of the studies in Supranuclear Palsy, Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03872102University of Texas Southwestern Medical CenterFacilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT04468932Oregon Health and Science UniversityTranscranial Magnetic Stimulation in Progressive Supranuclear Palsy | 2027-04 |
| NCT07863180Prabesh KanelTributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | 2027-05 |
| NCT05459753University of MichiganCholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
AMX0035 is a fixed dose combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This clinical trial is designed to demonstrate that AMX0035 is safe and tolerable, and to assess its effect on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS) over a 52-week double-blind phase. The Phase 2b and Phase 3 study portions are planned to feature an identical design: a randomized, double-blind, placebo-controlled phase that is followed by an optional open-label extension (OLE) phase. The phase 3 portion of ORION may be initiated based on results of the phase 2b Interim Analysis and/or the Primary Analysis and the totality of data from the Phase 2b study portion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMX0035 administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study For participants electing to continue into the open-label phase at Week 52; AMX0035 will be administered once daily for first 2 weeks and then twice daily for remainder of open-label phase
Drug: AMX0035
Placebo administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study
Other: Placebo
Proprietary formulation of sodium phenylbutyrate and taurursodiol
Matching Placebo Comparator
Change in total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score
Assess the impact of AMX0035 on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS); Total scores range from 0-96 with higher scores indicating more progressed disease
Time frame: 52 weeks
Change in total (10-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score
Assess the impact of AMX0035 on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS); Total scores range from 0-30 with higher scores indicating more progressed disease
Time frame: 52 weeks
Change in MDS-UPDRS Part II Score
To evaluate the efficacy of AMX0035 on motor aspects of activities of daily living as measured on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-PDRS) Part II; Total scores range from 0-52 with lower scores indicating better function
Time frame: 52 weeks
Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Safety and tolerability of AMX0035 in participants with PSP
Time frame: 52 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Sep 2025, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium phenylbutyrate and taurursodiol
Supranuclear Palsy, Progressive →
Amylyx Pharmaceuticals Inc.